Teva Pharmaceuticals adds Pristiq 1 generic to portfolio

Teva Pharmaceutical Industries Ltd. has launched generic Pristiq 1 (desvenlafaxine) extended-release tablets in 25, 50 and 100 mg in the United States. 
Desvenlafaxine is a seretonin and norepinephrine reuptake inhibitor that is highly useful for individuals suffering from major depressive disorder. The credentials of the medication have been solidified through four short-term placebo-controlled studies in certain adult outpatients.
Pristiq had annual sales of $883 million approximately, based on IMS data in December 2016.
The new generic extended-release tablets are highly anticipated, both in their ability to aid with depression disorders and to build up the pharmaceutical company's portfolio, which already boasts nearly 600 generic medications. 
Teva has over 100 pending first-to-files in the U.S. One in six generic prescriptions dispensed in the U.S. is a Teva generic medication.